Høiseth Arne Didrik, Brynildsen Jon, Hagve Tor-Arne, Christensen Geir, Søyseth Vidar, Omland Torbjørn, Røsjø Helge
a Division of Medicine , Akershus University Hospital , Lørenskog , Norway .
b Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine; University of Oslo , Oslo , Norway .
Biomarkers. 2016;21(2):173-9. doi: 10.3109/1354750X.2015.1126645. Epub 2016 Jan 12.
Troponin (hs-TnT) levels predict mortality after acute exacerbation of COPD (AECOPD). Whether this is independent of heart failure (HF) is not established.
Prospectively included AECOPD patients adjudicated for acute HF categorized into three groups: (A) AECOPD, but acute HF the primary cause for hospitalization; (B) AECOPD the primary cause, but co-existing myocardial dysfunction and (C) AECOPD without myocardial dysfunction.
About 103 AECOPD patients; 18% A, 27% B and 54% C. Hs-TnT level differed between the groups: (ng/l, median) A: 41, B: 25 and C: 15, p = 0.03 for A versus B and p = 0.005 for B versus C. During a median 826 days, 47% died. In Cox analysis, hs-TnT levels remained associated with mortality (hazard ratio per 10 ng/l 1.3, p < 0.0001).
hs-TnT levels are influenced by myocardial dysfunction/HF in AECOPD, but provide independent prognostic information. The prognostic merit of hs-TnT cannot be attributed to HF alone.
肌钙蛋白(高敏肌钙蛋白T)水平可预测慢性阻塞性肺疾病急性加重期(AECOPD)后的死亡率。但这是否独立于心力衰竭(HF)尚不清楚。
前瞻性纳入因急性心力衰竭而被判定的AECOPD患者,分为三组:(A)AECOPD,但急性心力衰竭是住院的主要原因;(B)AECOPD是主要原因,但并存心肌功能障碍;(C)AECOPD无心肌功能障碍。
约103例AECOPD患者;18%为A组,27%为B组,54%为C组。各组间高敏肌钙蛋白T水平不同:(ng/l,中位数)A组:41,B组:25,C组:15,A组与B组比较p = 0.03,B组与C组比较p = 0.005。在中位826天期间,47%的患者死亡。在Cox分析中,高敏肌钙蛋白T水平仍与死亡率相关(每10 ng/l的风险比为1.3,p < 0.0001)。
AECOPD患者的高敏肌钙蛋白T水平受心肌功能障碍/心力衰竭影响,但可提供独立的预后信息。高敏肌钙蛋白T的预后价值不能仅归因于心力衰竭。